[go: up one dir, main page]

DE69800699D1 - Verbindungen - Google Patents

Verbindungen

Info

Publication number
DE69800699D1
DE69800699D1 DE69800699T DE69800699T DE69800699D1 DE 69800699 D1 DE69800699 D1 DE 69800699D1 DE 69800699 T DE69800699 T DE 69800699T DE 69800699 T DE69800699 T DE 69800699T DE 69800699 D1 DE69800699 D1 DE 69800699D1
Authority
DE
Germany
Prior art keywords
pct
sec
date
pub
links
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69800699T
Other languages
English (en)
Other versions
DE69800699T2 (de
Inventor
Nicholas Kindon
Premji Meghani
Stephen Thom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE69800699D1 publication Critical patent/DE69800699D1/de
Application granted granted Critical
Publication of DE69800699T2 publication Critical patent/DE69800699T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal (AREA)
  • Valve-Gear Or Valve Arrangements (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69800699T 1997-05-28 1998-05-18 Verbindungen Expired - Fee Related DE69800699T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702002A SE9702002D0 (sv) 1997-05-28 1997-05-28 Novel compounds
PCT/SE1998/000940 WO1998054180A1 (en) 1997-05-28 1998-05-18 Novel compounds

Publications (2)

Publication Number Publication Date
DE69800699D1 true DE69800699D1 (de) 2001-05-17
DE69800699T2 DE69800699T2 (de) 2001-09-06

Family

ID=20407125

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69800699T Expired - Fee Related DE69800699T2 (de) 1997-05-28 1998-05-18 Verbindungen

Country Status (12)

Country Link
US (1) US6162808A (de)
EP (1) EP0984963B1 (de)
JP (1) JP2002501528A (de)
AT (1) ATE200489T1 (de)
AU (1) AU7681198A (de)
DE (1) DE69800699T2 (de)
DK (1) DK0984963T3 (de)
ES (1) ES2156444T3 (de)
GR (1) GR3036195T3 (de)
PT (1) PT984963E (de)
SE (1) SE9702002D0 (de)
WO (1) WO1998054180A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE213242T1 (de) * 1997-11-21 2002-02-15 Astrazeneca Uk Ltd Neue verbindungen, welche antagonisten sind für p2-purinorezeptor 7-transmembran (tm) g-protein gekoppelte rezeptoren
EP1278777B1 (de) * 2000-04-21 2012-12-19 New England Medical Center G-protein gekoppelte rezeptor (gpcr)- agonisten und -antagonisten sowie verfahren zur gpcr-aktivierung/-inhibierung
US7696168B2 (en) * 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
US20030151980A1 (en) * 2002-02-13 2003-08-14 Isador Farash Color referenced multi-time watch
AUPS160602A0 (en) 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
AU2002952086A0 (en) * 2002-10-16 2002-11-07 The University Of Queensland Treatment of osteoarthritis
US8440627B2 (en) * 2004-11-04 2013-05-14 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of use
US7589213B2 (en) 2007-04-27 2009-09-15 Old David W Therapeutic substituted lactams
WO2009140205A2 (en) 2008-05-15 2009-11-19 Allergan, Inc. Therapeutic substituted cyclopentanes
CN103159641A (zh) * 2011-12-14 2013-06-19 天津泰普药品科技发展有限公司 托伐普坦中间体2-甲酸-5-(2-甲基苯甲酰氨基)甲苯的制备方法
EP2881390A1 (de) 2013-12-04 2015-06-10 Sanofi Thienomethylpiperazinderivate als Inhibitoren der löslichen Epoxidhydrolase
CN106045937B (zh) * 2016-06-21 2019-04-16 杭州诺维和医药技术有限公司 一种{2-[2-(2-氨基-4-噻唑基)-乙酰基氨基]-4-噻唑基}-乙酸的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356898A (en) * 1991-01-31 1994-10-18 Warner-Lambert Company Substituted 4,6-di-tertiary-butyl 5-hydroxy-pyrimidines
IT1277373B1 (it) * 1995-07-28 1997-11-10 Consiglio Nazionale Ricerche Impiego di composti agonisti o antagonisti dei recettori purinici p2 per la prevenzione della citotossicita' da glutammato

Also Published As

Publication number Publication date
GR3036195T3 (en) 2001-10-31
SE9702002D0 (sv) 1997-05-28
JP2002501528A (ja) 2002-01-15
DK0984963T3 (da) 2001-06-05
AU7681198A (en) 1998-12-30
ATE200489T1 (de) 2001-04-15
ES2156444T3 (es) 2001-06-16
US6162808A (en) 2000-12-19
EP0984963B1 (de) 2001-04-11
PT984963E (pt) 2001-07-31
EP0984963A1 (de) 2000-03-15
DE69800699T2 (de) 2001-09-06
WO1998054180A1 (en) 1998-12-03

Similar Documents

Publication Publication Date Title
SE9702651D0 (sv) Novel compounds
EP0903349A3 (de) CCR-3-Rezeptor-Antagonisten
BR0015963A (pt) Compostos de uréia antagonistas receptor muscarìnico, composições farmacêuticas compreendendo tais compostos e método de preparação destes compostos
WO2003086303A3 (en) Farnesoid x-activated receptor agonists
ES2160525A1 (es) Derivados de la 4-aroilpiperidina antagonistas de los receptores ccr-3
MY122392A (en) Adamantane derivatives of use of p2x7 receptor antagonists, a process for their preparation, pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions
NO983002L (no) Vitronectin-reseptor-antagonister
ES2158813A1 (es) Sales cuaternarias de piperidina antagonistas del receptor ccr-3
DE69932173D1 (de) Adenine-derivate
DE69532162D1 (de) Cannabinoid-rezeptor-antagonisten
NO20032253L (no) Piperazinylpyrazinforbindelser som antagonister av serotonin 5-HT2-reseptorer
ATE200489T1 (de) Verbindungen
HUP0100705A2 (hu) Hatóanyag-kombinációk alkalmazása, valamint ilyen kombinációkat tartalmazó gyógyszerkészítmények és készletek impotencia kezelésére
MX9801890A (es) Nuevos compuestos antagonistas selectivos del receptor nk3 humano, procedimiento para su obtencion y composiciones farmaceuticas que los contienen.
SE9702794D0 (sv) New compounds
NO996442L (no) Anvendelse av en spesifikk antagonist for 5HT2 reseptorer for fremstilling av medisiner som er anvendbare for behandling av søvnapnésyndromet
NO963331L (no) 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister
ES2172939T3 (es) Nuevos compuestos que son antagonistas de receptores acoplados a proteina g de 7-transmembrana (tm) de p2-purinoceptores.
NO995685L (no) Nye glycosylerte ginkgolidderivater, anvendelse derav som medikamenter og farmasoeytiske blandinger
HUP0004900A2 (hu) Mozgászavarok kezelésére szolgáló, hatóanyagként NMDA-receptor antagonista hatású piperidinszármazékokat tartalmazó gyógyszerkészítmények
ATE384066T1 (de) Thieno-pyrrole verbindungen als antagonisten der gonadotropin-freisetzenden hormonrezeptoren
NO20000654L (no) 1,3-dioksolo/4.5-H/2.3/Benzodiazepinderivater som AMPA/kainareseptorinhibitorer
ECSP972049A (es) Derivados de lactama

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee